Claims:

1. A pharmaceutical composition comprising

a) an inner extended release core comprising metformin (particularly metformin hydrochloride) and one or more excipients;

b) an optional intermediate seal coating; and

c) an outer immediate release coating comprising at least one active pharmaceutical ingredient namely

a SGLT-2 inhibitor, which is 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((*S*)-tetrahydrofuran-3-yloxy)-benzyl]-benzene,

and one or more excipients;

2. The pharmaceutical composition according to claim 1, wherein the inner extended release core a) is a formulation comprising metformin hydrochloride, a swellable and/or extended release polymer, and one or more further excipients.

3. The pharmaceutical composition according to claim 2, in which the swellable and/or extended release polymer is a combination of poly(ethylene oxide) and hydroxypropyl methylcellulose (HPMC).

4. The pharmaceutical composition according to claim 3, wherein in the inner extended release core the weight ratio of the poly(ethylene oxide) and hydroxypropyl methylcellulose (HPMC) in combination constitutes from about 30% to about 65%, or from about 40% to about 50%, by weight of the inner extended release core.

~~15~~. A pharmaceutical composition comprising

a) an inner extended release core comprising metformin (particularly metformin hydrochloride) and one or more excipients;

b) an optional intermediate seal coating; and

c) an outer immediate release coating comprising at least one active pharmaceutical ingredient ~~selected from~~namely

a DPP-4 inhibitor, ~~preferably~~ which is linagliptin, ~~and~~

~~a SGLT-2 inhibitor, preferably 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((*S*)-tetrahydrofuran-3-yloxy)-benzyl]-benzene,~~

and one or more excipients~~.~~;

~~2. The pharmaceutical composition according to claim 1,~~ wherein the inner extended release core a) is a formulation comprising metformin hydrochloride, a swellable and/or extended release polymer, and one or more further excipients, in which the swellable and/or extended release polymer is a combination of poly(ethylene oxide) and hydroxypropyl methylcellulose (HPMC).

6. The pharmaceutical composition according to claim 5, wherein in the inner extended release core the weight ratio of the poly(ethylene oxide) and hydroxypropyl methylcellulose (HPMC) in combination constitutes from about 30% to about 65%, or from about 40% to about 50%, by weight of the inner extended release core.

~~3~~7. The pharmaceutical composition according to claim ~~1~~5 or ~~2~~6, wherein the outer immediate release coating c) is a film coat formulation comprising linagliptin, L-arginine as stabilizer, a film-coating agent, a plasticizer, and, optionally, a glidant.

~~4~~8. The pharmaceutical composition according to claim ~~3~~7, wherein the weight ratio of the L-arginine to linagliptin is within the range from about 2:1 to about 1:1, or up to about 0.2:1.

~~5~~9. The pharmaceutical composition according to claim 1, 2, 3 or ~~2~~4, wherein the outer immediate release coating c) is a film coat formulation comprising 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((*S*)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a film-coating agent, a plasticizer, and, optionally, a glidant.

~~6~~10. The pharmaceutical composition according to claim ~~3~~7, ~~4~~8 or ~~5~~9, wherein the film-coating agent is hydroxypropyl methylcellulose~~, e.g. Hypromellose 2910, Methocel E5, or Methocel E15~~.

~~7~~11. The pharmaceutical composition according to claim ~~3~~7, ~~4~~8, ~~5~~9 or ~~6~~10, wherein the plastizicer is polyethylene glycol~~, e.g. Macrogol 400, 6000 or 8000~~.

~~8~~12. The pharmaceutical composition according to claim ~~3~~7, ~~4~~8, ~~5-~~9 or ~~6~~10, wherein the plastizicer is propylene glycol.

~~9~~13. The pharmaceutical composition according to claim ~~3~~7, ~~4~~8, ~~5~~9, ~~6~~10, ~~7-~~11 or ~~8~~ 12, wherein the optional glidant is talc.

~~10~~14. The pharmaceutical composition according to any one of the claims 1 to ~~9~~13, wherein the seal coating is present.

~~11~~15. The pharmaceutical composition according to claim ~~10~~14, wherein the seal coating comprises a film-coating agent, a plasticizer, and, optionally, a glidant, one or more pigments and/or colors.

~~12~~16. The pharmaceutical composition according to any one of the claims 1 to ~~9~~13, wherein the seal coating is absent.

~~13~~17. The pharmaceutical composition according to any one of the preceding claims, wherein the metformin hydrochloride is present in an unit dosage strength of 500, 750, 850, 1000 or 1500 mg.

~~14~~18. The pharmaceutical composition according to any one of the ~~preceding~~ claims 5 to 8, 10 to 17, wherein the linagliptin is present in an unit dosage strength of 0.5, 1, 2.5 or 5 mg.

~~15~~19. The pharmaceutical composition according to any one of the ~~preceding~~ claims 1 to 4, 9 to 17, wherein the 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((*S*)-tetrahydrofuran-3-yloxy)-benzyl]-benzene is present in an unit dosage strength of 5, 10, 12.5 or 25 mg.

~~16~~20. The pharmaceutical composition according to any of the preceding claims, which is a tablet for oral administration.

~~17~~21. The tablet according to claim ~~16-~~20 further comprising an outer film over-coat.

~~18~~22. The tablet according to claim ~~17~~21, wherein the outer film over-coat comprises a film-coating agent, a plasticizer, and, optionally, a glidant, one or more pigments and/or colors.

~~19~~23. The pharmaceutical composition according to any of the preceding claim for use in treating and/or preventing (including slowing the progression and/or delaying the onset) of metabolic diseases, especially type 2 diabetes mellitus and conditions related thereto (~~e.g.~~ including diabetic complications),
either in type 2 diabetes patients who have not been previously treated with an antihyperglycemic agent,
or in type 2 diabetes patients with insufficient glycemic control despite therapy with one or two conventional antihyperglycemic agents selected from metformin, sulphonylureas, thiazolidinediones ~~(e.g. pioglitazone)~~, glinides, alpha-glucosidase blockers, GLP-1 or GLP-1 analogues, and insulin or insulin analogues.

24. The pharmaceutical composition according to claim 7, wherein said pharmaceutical composition comprises 0.5 mg to 10 mg of L-arginine.